Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BGB A3055

Next Previous
Drug Profile

BGB A3055

Alternative Names: BGB-A3055

Latest Information Update: 22 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Developer BeOne Medicines
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 29 May 2026 Pharmacodynamics, efficacy and adverse events data from a phase I trial in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (AACR-2026)
  • 27 Jan 2026 BeiGene terminates a phase Ia/Ib trial in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy, Combination therapy) in Australia, USA, China, France and South Korea (IV), as the decision was conducted by the sponsor and not driven by safety concerns as no new safety signals have been observed in the program (NCT05935098)
  • 14 Oct 2025 BGB A3055 is still in phase I trials for Solid tumours (Combination therapy, Late stage disease, Metastatic disease, Second line therapy or greater) in Australia, US, China, France and South Korea (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top